Participated in SRTD Biotech's oversubscribed EUR 31.5M seed round for mRNA therapeutics, led by Merieux Equity Partners.
NOV 2026
SRTD Biotech is developing seRNA, a modular precision RNA therapeutics platform that activates therapeutic effectors only after detecting disease-specific RNA inside target cells
SRTD Biotech is developing seRNA, a modular precision RNA therapeutics platform that activates therapeutic effectors only after detecting disease-specific RNA inside target cells. Its AI-powered discovery platform identifies RNA markers and optimizes constructs, while proprietary fusogenic lipid nanoparticles deliver them to target organs. Preclinical programs address hepatocellular carcinoma, lung cancer, liver fibrosis, and autoimmune diseases.